| dc.description.abstract | Objective: Pregabalin is an off-label drug used to reduce central neuropathy
pain that often accompanies and affects the quality of life in central post-stroke
pain (CPSP). This study was conducted to determine the effect of
pregabalin on CPSP. Methods: Patients with CPSP who were prescribed
pregabalin 75 mg/day for treatment were included in this study. The severity
of pain (worst, least, average, and right now) and the quality of life were
assessed with a Brief Pain Inventory (short form) (BPI-sf) questionnaire.
The assessment was conducted before treatment, in week 4, and at the
end of treatment (week 12). The Friedman test and, subsequently, the
Wilcoxon post-hoc test was conducted to compare the severity of pain and
the quality of life before and after therapy. Results: A total of 36 patients
with CPSP (21 male and 15 female) were included. The study found a
reduction in the severity of pain after four weeks of treatment and after 12
weeks of treatment (CI 95%, p<0.05). A minor change of the quality of life
significantly improved in week 4 in all sub-items of the BPI-sf questionnaire
(general activity, mood, walking ability, work, relations with others, sleep,enjoyment of life) (CI 95%, p <0.05). After 12 weeks of treatment, the
quality of life demonstrated a mild change in all sub-items. The major
adverse event shown in this study was somnolence (13.89%). Conclusion:
Pregabalin is safe and effective in reducing the severity of pain as well as
improving the quality of life in Indonesian patients with CPSP. | en_US |
